

Enoxaparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC)

OBJECTIVE

To evaluate the efficacy and safety of prophylactic low-molecular-weight heparin (enoxaparin) versus standard of care (no enoxaparin) in at-risk outpatients with COVID-19


PRIMARY OUTCOME

Death or hospitalisation within 21 days after randomisation

RESULTS

No difference in the outcomes between symptomatic patients with COVID-19 treated with enoxaparin versus standard of care


Trial profile



Inclusion criteria

- Symptomatic, confirmed COVID-19 diagnosis
- No COVID-19 vaccine at randomisation
- Age \geq 30 years
- At least one risk factor for severe disease

Cumulative survival probability by treatment group



Number at risk (number censored)

	0	7	14	21
Standard of care	114 (0)	104 (2)	100 (2)	99 (3)
Enoxaparin	105 (0)	95 (1)	91 (2)	91 (2)

REFERENCE:

Cools F et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. *Lancet Haematol.* 2022;9(8):e594-e604.



Scan to access the manuscript

